{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T11:52:23Z","timestamp":1782042743611,"version":"3.54.5"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,27]]},"DOI":"10.7759\/cureus.83082","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T16:21:49Z","timestamp":1745770909000},"source":"Crossref","is-referenced-by-count":6,"title":["Understanding and Managing Fracture Risk in Patients With Cancer: A Literature Review"],"prefix":"10.7759","author":[{"given":"Efstathios","family":"Kourtis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Zygogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Fanourgiakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Koulalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos D","family":"Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1724-9","article-title":"Prevalence of osteoporosis among cancer patients in Germany: prospective data from an oncological rehabilitation clinic","volume":"23","author":"Reuss-Borst M","year":"2012","unstructured":"Reuss-Borst M, Hartmann U, Scheede C, Wei\u00df J. Prevalence of osteoporosis among cancer patients in Germany: prospective data from an oncological rehabilitation clinic. Osteoporos Int. 2012, 23:1437-44. 10.1007\/s00198-011-1724-9","journal-title":"Osteoporos Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02353-4","article-title":"Fracture risk among patients with cancer compared to individuals without cancer: a population-based study","volume":"129","author":"Gong IY","year":"2023","unstructured":"Gong IY, Chan KK, Lipscombe LL, Cheung MC, Mozessohn L. Fracture risk among patients with cancer compared to individuals without cancer: a population-based study. Br J Cancer. 2023, 129:665-71. 10.1038\/s41416-023-02353-4","journal-title":"Br J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06542-4","article-title":"Fractures and long-term mortality in cancer patients: a population-based cohort study","volume":"33","author":"Ye C","year":"2022","unstructured":"Ye C, Leslie WD, Al-Azazi S, Yan L, Lix LM, Czaykowski P, Singh H. Fractures and long-term mortality in cancer patients: a population-based cohort study. Osteoporos Int. 2022, 33:2629-35. 10.1007\/s00198-022-06542-4","journal-title":"Osteoporos Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton LJ 3rd","year":"2005","unstructured":"Melton LJ 3rd, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005, 20:487-93. 10.1359\/JBMR.041131","journal-title":"J Bone Miner Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06631-4","article-title":"Fracture risk and assessment in adults with cancer","volume":"34","author":"Ye C","year":"2023","unstructured":"Ye C, Leslie WD. Fracture risk and assessment in adults with cancer. Osteoporos Int. 2023, 34:449-66. 10.1007\/s00198-022-06631-4","journal-title":"Osteoporos Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"13","author":"Center JR","year":"1999","unstructured":"Center JR, Nguyen TV, Schneider D, et al.. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999, 13:878-82. 10.1016\/S0140-6736(98)09075-8","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky001","article-title":"Postmenopausal fracture history and survival after reproductive cancer diagnosis","volume":"2","author":"Newcomb PA","year":"2018","unstructured":"Newcomb PA, Adams SV, Mayer S, et al.. Postmenopausal fracture history and survival after reproductive cancer diagnosis. JNCI Cancer Spectr. 2018, 2:pky001. 10.1093\/jncics\/pky001","journal-title":"JNCI Cancer Spectr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13441","article-title":"Admissions to hospital due to fracture in England in patients with prostate cancer treated with androgen-deprivation therapy - do we have to worry about the hormones?","volume":"118","author":"Jefferies ER","year":"2016","unstructured":"Jefferies ER, Bahl A, Hounsome L, Eylert MF, Verne J, Persad RA. Admissions to hospital due to fracture in England in patients with prostate cancer treated with androgen-deprivation therapy - do we have to worry about the hormones?. BJU Int. 2016, 118:416-22. 10.1111\/bju.13441","journal-title":"BJU Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7748\/ns2013.01.27.19.48.c9499","article-title":"Cancer-induced bone disease","volume":"27","author":"Drudge-Coates L","year":"2013","unstructured":"Drudge-Coates L, Turner B. Cancer-induced bone disease. Nurs Stand. 2013, 27:48-56; quiz 57. 10.7748\/ns2013.01.27.19.48.c9499","journal-title":"Nurs Stand"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study","volume":"165","author":"Chen Z","year":"2005","unstructured":"Chen Z, Maricic M, Bassford TL, et al.. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med. 2005, 165:552-8. 10.1001\/archinte.165.5.552","journal-title":"Arch Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802167490","article-title":"Fracture risk in patients with different types of cancer","volume":"48","author":"Vestergaard P","year":"2009","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with different types of cancer. Acta Oncol. 2009, 48:105-15. 10.1080\/02841860802167490","journal-title":"Acta Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1055\/a-2059-8830","article-title":"Association between papillary thyroid carcinoma and vertebral fracture","volume":"55","author":"Otani H","year":"2023","unstructured":"Otani H, Notsu M, Yamauchi M, Nawata K, Kanasaki K. Association between papillary thyroid carcinoma and vertebral fracture. Horm Metab Res. 2023, 55:592-8. 10.1055\/a-2059-8830","journal-title":"Horm Metab Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman RE","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006, 12:6243s-9s. 10.1158\/1078-0432.CCR-06-0931","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: An update on pathogenesis and management","volume":"7","author":"Mirrakhimov AE","year":"2015","unstructured":"Mirrakhimov AE. Hypercalcemia of malignancy: An update on pathogenesis and management. N Am J Med Sci. 2015, 7:483-93. 10.4103\/1947-2714.170600","journal-title":"N Am J Med Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08518-9","article-title":"Effect of cachexia on bone turnover in cancer patients: a case-control study","volume":"21","author":"Zwickl H","year":"2021","unstructured":"Zwickl H, Zwickl-Traxler E, Haushofer A, et al.. Effect of cachexia on bone turnover in cancer patients: a case-control study. BMC Cancer. 2021, 21:744. 10.1186\/s12885-021-08518-9","journal-title":"BMC Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13633","article-title":"Untangling fracture risk in monoclonal gammopathy of undetermined significance: a population-based cohort study","volume":"107","author":"R\u00f6gnvaldsson S","year":"2021","unstructured":"R\u00f6gnvaldsson S, Aspelund T, Thorsteinsd\u00f3ttir S, Turesson I, Bj\u00f6rkholm M, Landgren O, Kristinsson SY. Untangling fracture risk in monoclonal gammopathy of undetermined significance: a population-based cohort study. Eur J Haematol. 2021, 107:137-44. 10.1111\/ejh.13633","journal-title":"Eur J Haematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710303371806","article-title":"Falls, injuries due to falls, and the risk of admission to a nursing home","volume":"337","author":"Tinetti ME","year":"1997","unstructured":"Tinetti ME, Williams CS. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med. 1997, 337:1279-84. 10.1056\/NEJM199710303371806","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2014.10.003","article-title":"Systematic review of falls in older adults with cancer","volume":"6","author":"Wildes TM","year":"2015","unstructured":"Wildes TM, Dua P, Fowler SA, Miller JP, Carpenter CR, Avidan MS, Stark S. Systematic review of falls in older adults with cancer. J Geriatr Oncol. 2015, 6:70-83. 10.1016\/j.jgo.2014.10.003","journal-title":"J Geriatr Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.82.3.395","article-title":"Mortality, disability, and falls in older persons: the role of underlying disease and disability","volume":"82","author":"Dunn JE","year":"1992","unstructured":"Dunn JE, Rudberg MA, Furner SE, Cassel CK. Mortality, disability, and falls in older persons: the role of underlying disease and disability. Am J Public Health. 1992, 82:395-400. 10.2105\/ajph.82.3.395","journal-title":"Am J Public Health"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05619-2","article-title":"Falls in older adults with cancer: an updated systematic review of prevalence, injurious falls, and impact on cancer treatment","volume":"29","author":"Sattar S","year":"2021","unstructured":"Sattar S, Haase K, Kuster S, et al.. Falls in older adults with cancer: an updated systematic review of prevalence, injurious falls, and impact on cancer treatment. Support Care Cancer. 2021, 29:21-33. 10.1007\/s00520-020-05619-2","journal-title":"Support Care Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/rnj.0000000000000173","article-title":"Risk factors for falls in adult cancer survivors: an integrative review","volume":"43","author":"Campbell G","year":"2018","unstructured":"Campbell G, Wolfe RA, Klem ML. Risk factors for falls in adult cancer survivors: an integrative review. Rehabil Nurs. 2018, 43:201-13. 10.1097\/rnj.0000000000000173","journal-title":"Rehabil Nurs"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06392-4","article-title":"Sleep medication use and risk of fractures in breast cancer survivors","volume":"190","author":"Haque R","year":"2021","unstructured":"Haque R, Chlebowski RT, Chen L. Sleep medication use and risk of fractures in breast cancer survivors. Breast Cancer Res Treat. 2021, 190:541-8. 10.1007\/s10549-021-06392-4","journal-title":"Breast Cancer Res Treat"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23828","article-title":"Prostate-selective \u03b1 antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study","volume":"9","author":"Kao WH","year":"2018","unstructured":"Kao WH, Kuo CF, Chou IJ, et al.. Prostate-selective \u03b1 antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study. Oncotarget. 2018, 9:5263-73. 10.18632\/oncotarget.23828","journal-title":"Oncotarget"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2248","article-title":"Association of chronic obstructive pulmonary disease and smoking status with bone density and vertebral fractures in male lung cancer screening participants","volume":"29","author":"de Jong WU","year":"2014","unstructured":"de Jong WU, de Jong PA, Vliegenthart R, et al.. Association of chronic obstructive pulmonary disease and smoking status with bone density and vertebral fractures in male lung cancer screening participants. J Bone Miner Res. 2014, 29:2224-9. 10.1002\/jbmr.2248","journal-title":"J Bone Miner Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3661-3","article-title":"The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom","volume":"155","author":"Schmidt N","year":"2016","unstructured":"Schmidt N, Jacob L, Coleman R, Kostev K, Hadji P. The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat. 2016, 155:151-7. 10.1007\/s10549-015-3661-3","journal-title":"Breast Cancer Res Treat"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-013-0154-3","article-title":"Osteoporosis and cancer","volume":"11","author":"Drake MT","year":"2013","unstructured":"Drake MT. Osteoporosis and cancer. Curr Osteoporos Rep. 2013, 11:163-70. 10.1007\/s11914-013-0154-3","journal-title":"Curr Osteoporos Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-018-0060-9","article-title":"Diabetes mellitus and bone health: epidemiology, etiology and implications for fracture risk stratification","volume":"4","author":"Valderr\u00e1bano RJ","year":"2018","unstructured":"Valderr\u00e1bano RJ, Linares MI. Diabetes mellitus and bone health: epidemiology, etiology and implications for fracture risk stratification. Clin Diabetes Endocrinol. 2018, 4:9. 10.1186\/s40842-018-0060-9","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3109\/13685538.2015.1046043","article-title":"Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer","volume":"18","author":"Teoh JY","year":"2015","unstructured":"Teoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS, Ng CF. Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer. Aging Male. 2015, 18:180-5. 10.3109\/13685538.2015.1046043","journal-title":"Aging Male"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006983","article-title":"Bone fracture risk in patients with rheumatoid arthritis: a meta-analysis","volume":"96","author":"Xue AL","year":"2017","unstructured":"Xue AL, Wu SY, Jiang L, Feng AM, Guo HF, Zhao P. Bone fracture risk in patients with rheumatoid arthritis: a meta-analysis. Medicine (Baltimore). 2017, 96:e6983. 10.1097\/MD.0000000000006983","journal-title":"Medicine (Baltimore)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100292","article-title":"Influence of chemotherapy and endocrine treatment on fractures in postmenopausal women with breast cancer - a retrospective cohort study","volume":"22","author":"Stumpf U","year":"2020","unstructured":"Stumpf U, Kostev K, Siebenb\u00fcrger G, B\u00f6cker W, Hadji P. Influence of chemotherapy and endocrine treatment on fractures in postmenopausal women with breast cancer - a retrospective cohort study. J Bone Oncol. 2020, 22:100292. 10.1016\/j.jbo.2020.100292","journal-title":"J Bone Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1615\/critreveukargeneexpr.v19.i1.20","article-title":"Cancer treatment-related bone disease","volume":"19","author":"Brown SA","year":"2009","unstructured":"Brown SA, Guise TA. Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr. 2009, 19:47-60. 10.1615\/critreveukargeneexpr.v19.i1.20","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.58","article-title":"Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer","volume":"61","author":"Bruning PF","year":"1990","unstructured":"Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer. 1990, 61:308-10. 10.1038\/bjc.1990.58","journal-title":"Br J Cancer"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-023-01231-z","article-title":"Cytotoxic chemotherapy is associated with decreased bone mineral density in postmenopausal women with early and locally advanced breast cancer","volume":"18","author":"Nisha Y","year":"2023","unstructured":"Nisha Y, Dubashi B, Bobby Z, Sahoo JP, Kayal S, Ananthakrishnan R, Ganesan P. Cytotoxic chemotherapy is associated with decreased bone mineral density in postmenopausal women with early and locally advanced breast cancer. Arch Osteoporos. 2023, 18:41. 10.1007\/s11657-023-01231-z","journal-title":"Arch Osteoporos"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1310839","article-title":"Effect of methotrexate on bone and wound healing","volume":"16","author":"Pountos I","year":"2017","unstructured":"Pountos I, Giannoudis PV. Effect of methotrexate on bone and wound healing. Expert Opin Drug Saf. 2017, 16:535-45. 10.1080\/14740338.2017.1310839","journal-title":"Expert Opin Drug Saf"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/jor.22527","article-title":"Cisplatin inhibits bone healing during distraction osteogenesis","volume":"32","author":"Stine KC","year":"2014","unstructured":"Stine KC, Wahl EC, Liu L, et al.. Cisplatin inhibits bone healing during distraction osteogenesis. J Orthop Res. 2014, 32:464-70. 10.1002\/jor.22527","journal-title":"J Orthop Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(95)00194-i","article-title":"Bone and cancer: pathophysiology and treatment of metastases","volume":"17","author":"Kanis JA","year":"1995","unstructured":"Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone. 1995, 17:101. 10.1016\/8756-3282(95)00194-i","journal-title":"Bone"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1080\/02841860601166958","article-title":"Gonadal dysfunction and fertility problems in cancer survivors","volume":"46","author":"Bryd\u00f8y M","year":"2007","unstructured":"Bryd\u00f8y M, Foss\u00e5 SD, Dahl O, Bj\u00f8ro T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol. 2007, 46:480-9. 10.1080\/02841860601166958","journal-title":"Acta Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147484","article-title":"Molecular mechanism and prevention strategy of chemotherapy- and radiotherapy-induced ovarian damage","volume":"13","author":"Kim S","year":"2021","unstructured":"Kim S, Kim SW, Han SJ, Lee S, Park HT, Song JY, Kim T. Molecular mechanism and prevention strategy of chemotherapy- and radiotherapy-induced ovarian damage. Int J Mol Sci. 2021, 13:22. 10.3390\/ijms22147484","journal-title":"Int J Mol Sci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115787","article-title":"Chemotherapy-induced gastrointestinal toxicity: pathogenesis and current management","volume":"216","author":"He Y","year":"2023","unstructured":"He Y, Zheng J, Ye B, Dai Y, Nie K. Chemotherapy-induced gastrointestinal toxicity: pathogenesis and current management. Biochem Pharmacol. 2023, 216:115787. 10.1016\/j.bcp.2023.115787","journal-title":"Biochem Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2013.10.002","article-title":"Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study","volume":"5","author":"Ward PR","year":"2014","unstructured":"Ward PR, Wong MD, Moore R, Naeim A. Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study. J Geriatr Oncol. 2014, 5:57-64. 10.1016\/j.jgo.2013.10.002","journal-title":"J Geriatr Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0383","article-title":"The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling","volume":"73","author":"Kolb NA","year":"2016","unstructured":"Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, Mooney K. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 2016, 73:860-6. 10.1001\/jamaneurol.2016.0383","journal-title":"JAMA Neurol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00317-3","article-title":"Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment","volume":"37","author":"Vehmanen L","year":"2001","unstructured":"Vehmanen L, Saarto T, Elomaa I, M\u00e4kel\u00e4 P, V\u00e4lim\u00e4ki M, Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer. 2001, 37:2373-8. 10.1016\/s0959-8049(01)00317-3","journal-title":"Eur J Cancer"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-10-1121","article-title":"Bone loss and fracture risk associated with cancer therapy","volume":"11","author":"Guise TA","year":"2006","unstructured":"Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist. 2006, 11:1121-31. 10.1634\/theoncologist.11-10-1121","journal-title":"Oncologist"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2015.09.004","article-title":"Treatment-related fractures after combined modality therapy for soft tissue sarcomas of the proximal lower extremity: can the risk be mitigated?","volume":"6","author":"Bishop AJ","year":"2016","unstructured":"Bishop AJ, Zagars GK, Allen PK, Moon BS, Lin PP, Lewis VO, Guadagnolo BA. Treatment-related fractures after combined modality therapy for soft tissue sarcomas of the proximal lower extremity: can the risk be mitigated?. Pract Radiat Oncol. 2016, 6:194-200. 10.1016\/j.prro.2015.09.004","journal-title":"Pract Radiat Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1722","article-title":"Changes in bone mineral density in newly diagnosed testicular cancer patients after anticancer treatment","volume":"99","author":"Willemse PM","year":"2014","unstructured":"Willemse PM, Hamdy NA, de Kam ML, Burggraaf J, Osanto S. Changes in bone mineral density in newly diagnosed testicular cancer patients after anticancer treatment. J Clin Endocrinol Metab. 2014, 99:4101-8. 10.1210\/jc.2014-1722","journal-title":"J Clin Endocrinol Metab"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20160885","article-title":"Pelvic insufficiency fracture (PIF) incidence in patients treated with intensity-modulated radiation therapy (IMRT) for gynaecological or anal cancer: single-institution experience and review of the literature","volume":"90","author":"Bazire L","year":"2017","unstructured":"Bazire L, Xu H, Foy JP, et al.. Pelvic insufficiency fracture (PIF) incidence in patients treated with intensity-modulated radiation therapy (IMRT) for gynaecological or anal cancer: single-institution experience and review of the literature. Br J Radiol. 2017, 90:20160885. 10.1259\/bjr.20160885","journal-title":"Br J Radiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.10.006","article-title":"Risk of pelvic fracture with radiation therapy in older patients","volume":"106","author":"Vitzthum LK","year":"2020","unstructured":"Vitzthum LK, Park H, Zakeri K, et al.. Risk of pelvic fracture with radiation therapy in older patients. Int J Radiat Oncol Biol Phys. 2020, 106:485-92. 10.1016\/j.ijrobp.2019.10.006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176377","article-title":"The influence of radiation on bone and bone cells-differential effects on osteoclasts and osteoblasts","volume":"21","author":"Donaubauer AJ","year":"2020","unstructured":"Donaubauer AJ, Deloch L, Becker I, Fietkau R, Frey B, Gaipl US. The influence of radiation on bone and bone cells-differential effects on osteoclasts and osteoblasts. Int J Mol Sci. 2020, 21:10.3390\/ijms21176377","journal-title":"Int J Mol Sci"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100650","article-title":"Pelvic insufficiency fractures after intensity modulated radiation therapy combined with chemotherapy for cervix carcinoma: incidence and impact of bone mineral density","volume":"41","author":"Duranson A","year":"2023","unstructured":"Duranson A, Thevenet V, Guyon F, et al.. Pelvic insufficiency fractures after intensity modulated radiation therapy combined with chemotherapy for cervix carcinoma: incidence and impact of bone mineral density. Clin Transl Radiat Oncol. 2023, 41:100650. 10.1016\/j.ctro.2023.100650","journal-title":"Clin Transl Radiat Oncol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2030","article-title":"Increased risk of pelvic fracture after radiotherapy in rectal cancer survivors: a propensity matched study","volume":"8","author":"Kang YM","year":"2019","unstructured":"Kang YM, Chao TF, Wang TH, Hu YW. Increased risk of pelvic fracture after radiotherapy in rectal cancer survivors: a propensity matched study. Cancer Med. 2019, 8:3639-47. 10.1002\/cam4.2030","journal-title":"Cancer Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac197","article-title":"Long-term pelvic fracture and overall mortality risk after pelvic cancer and pelvic radiation","volume":"115","author":"Nelson RA","year":"2023","unstructured":"Nelson RA, Blakely AM, Larson JC, et al.. Long-term pelvic fracture and overall mortality risk after pelvic cancer and pelvic radiation. J Natl Cancer Inst. 2023, 115:104-11. 10.1093\/jnci\/djac197","journal-title":"J Natl Cancer Inst"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100656","article-title":"Short-course preoperative radiotherapy increases pelvic fracture risk in rectal cancer","volume":"42","author":"Vesa V","year":"2023","unstructured":"Vesa V, Jaana M, Ia K, et al.. Short-course preoperative radiotherapy increases pelvic fracture risk in rectal cancer. Clin Transl Radiat Oncol. 2023, 42:100656. 10.1016\/j.ctro.2023.100656","journal-title":"Clin Transl Radiat Oncol"},{"key":"ref53","article-title":"Bone density and fracture risk following SBRT for non-spine bone metastases","volume":"7","author":"Cao Y","year":"2021","unstructured":"Cao Y, Stachelek GC, Fu W, et al.. Bone density and fracture risk following SBRT for non-spine bone metastases. J Radiosurg SBRT. 2021, 7:199-206.","journal-title":"J Radiosurg SBRT"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.03.030","article-title":"Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases","volume":"127","author":"Erler D","year":"2018","unstructured":"Erler D, Brotherston D, Sahgal A, et al.. Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases. Radiother Oncol. 2018, 127:304-9. 10.1016\/j.radonc.2018.03.030","journal-title":"Radiother Oncol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyab164","article-title":"Fracture risk following stereotactic body radiotherapy for long bone metastases","volume":"52","author":"Ito K","year":"2022","unstructured":"Ito K, Nakajima Y, Ogawa H, Taguchi K. Fracture risk following stereotactic body radiotherapy for long bone metastases. Jpn J Clin Oncol. 2022, 52:47-52. 10.1093\/jjco\/hyab164","journal-title":"Jpn J Clin Oncol"},{"key":"ref56","article-title":"A volumetric dosimetry analysis of vertebral body fracture risk after single fraction spine stereotactic body radiation therapy","volume":"11","author":"Lee MY","year":"2021","unstructured":"Lee MY, Ouyang Z, LaHurd D, et al.. A volumetric dosimetry analysis of vertebral body fracture risk after single fraction spine stereotactic body radiation therapy. Pract Radiat Oncol. 2021, 11:480-7.","journal-title":"Pract Radiat Oncol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.04.002","article-title":"Local failure and vertebral body fracture risk using multifraction stereotactic body radiation therapy for spine metastases","volume":"3","author":"Mehta N","year":"2018","unstructured":"Mehta N, Zavitsanos PJ, Moldovan K, et al.. Local failure and vertebral body fracture risk using multifraction stereotactic body radiation therapy for spine metastases. Adv Radiat Oncol. 2018, 3:245-51. 10.1016\/j.adro.2018.04.002","journal-title":"Adv Radiat Oncol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-017-1109-x","article-title":"External-beam radiation therapy combined with limb-sparing surgery in elderly patients (>70 years) with primary soft tissue sarcomas of the extremities: a retrospective analysis","volume":"193","author":"Andr\u00e4 C","year":"2017","unstructured":"Andr\u00e4 C, Klein A, D\u00fcrr HR, et al.. External-beam radiation therapy combined with limb-sparing surgery in elderly patients (>70 years) with primary soft tissue sarcomas of the extremities: a retrospective analysis. Strahlenther Onkol. 2017, 193:604-11. 10.1007\/s00066-017-1109-x","journal-title":"Strahlenther Onkol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07182-5","article-title":"Femoral fracture in primary soft-tissue sarcoma of the thigh and groin treated with intensity-modulated radiation therapy: observed versus expected risk","volume":"26","author":"Folkert MR","year":"2019","unstructured":"Folkert MR, Casey DL, Berry SL, Crago A, Fabbri N, Singer S, Alektiar KM. Femoral fracture in primary soft-tissue sarcoma of the thigh and groin treated with intensity-modulated radiation therapy: observed versus expected risk. Ann Surg Oncol. 2019, 26:1326-31. 10.1245\/s10434-019-07182-5","journal-title":"Ann Surg Oncol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04796-w","article-title":"Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223","volume":"47","author":"Caffo O","year":"2020","unstructured":"Caffo O, Frantellizzi V, Tucci M, et al.. Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. Eur J Nucl Med Mol Imaging. 2020, 47:2633-8. 10.1007\/s00259-020-04796-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.03.020","article-title":"Fracture risk in men with metastatic prostate cancer treated with radium-223","volume":"19","author":"Hijab A","year":"2021","unstructured":"Hijab A, Curcean S, Tunariu N, et al.. Fracture risk in men with metastatic prostate cancer treated with radium-223. Clin Genitourin Cancer. 2021, 19:e299-305. 10.1016\/j.clgc.2021.03.020","journal-title":"Clin Genitourin Cancer"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0236-0","article-title":"Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone\/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer","volume":"23","author":"Shore N","year":"2020","unstructured":"Shore N, Higano CS, George DJ, et al.. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone\/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020, 23:680-8. 10.1038\/s41391-020-0236-0","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130725","article-title":"Fracture risk and adjuvant therapies in young breast cancer patients: a population-based study","volume":"10","author":"Chang CH","year":"2015","unstructured":"Chang CH, Chen SJ, Liu CY. Fracture risk and adjuvant therapies in young breast cancer patients: a population-based study. PLoS One. 2015, 10:e0130725. 10.1371\/journal.pone.0130725","journal-title":"PLoS One"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrx038","article-title":"Fracture after radiation therapy for femoral metastasis: incidence, timing and clinical features","volume":"58","author":"Shimoyama T","year":"2017","unstructured":"Shimoyama T, Katagiri H, Harada H, et al.. Fracture after radiation therapy for femoral metastasis: incidence, timing and clinical features. J Radiat Res. 2017, 58:661-8. 10.1093\/jrr\/rrx038","journal-title":"J Radiat Res"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.07.013","article-title":"Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis","volume":"69","author":"Hadji P","year":"2009","unstructured":"Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol. 2009, 69:73-82. 10.1016\/j.critrevonc.2008.07.013","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.652979","article-title":"Risk of fracture during androgen deprivation therapy among patients with prostate cancer: a systematic review and meta-analysis of cohort studies","volume":"12","author":"Wu CC","year":"2021","unstructured":"Wu CC, Chen PY, Wang SW, et al.. Risk of fracture during androgen deprivation therapy among patients with prostate cancer: a systematic review and meta-analysis of cohort studies. Front Pharmacol. 2021, 12:652979. 10.3389\/fphar.2021.652979","journal-title":"Front Pharmacol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-015-0046-x","article-title":"Negative impact of aromatase inhibitors on proximal femoral bone mass and geometry in postmenopausal women with breast cancer","volume":"97","author":"Lee SJ","year":"2015","unstructured":"Lee SJ, Kim KM, Brown JK, et al..  Negative impact of aromatase inhibitors on proximal femoral bone mass and geometry in postmenopausal women with breast cancer. Calcif Tissue Int. 2015, 97:551-9. 10.1007\/s00223-015-0046-x","journal-title":"Calcif Tissue Int"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2021.1936485","article-title":"Selective estrogen receptor modulators and bone health","volume":"25","author":"Goldstein SR","year":"2022","unstructured":"Goldstein SR. Selective estrogen receptor modulators and bone health. Climacteric. 2022, 25:56-9. 10.1080\/13697137.2021.1936485","journal-title":"Climacteric"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00366","article-title":"Effect of tamoxifen on the risk of osteoporosis and osteoporotic fracture in younger breast cancer survivors: a nationwide study","volume":"10","author":"Lee J","year":"2020","unstructured":"Lee J, Alqudaihi HM, Kang MS, et al.. Effect of tamoxifen on the risk of osteoporosis and osteoporotic fracture in younger breast cancer survivors: a nationwide study. Front Oncol. 2020, 10:366. 10.3389\/fonc.2020.00366","journal-title":"Front Oncol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.7123","article-title":"Tamoxifen use and osteoporotic fracture risk: a population-based analysis","volume":"26","author":"Cooke AL","year":"2008","unstructured":"Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD. Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol. 2008, 26:5227-32. 10.1200\/JCO.2007.15.7123","journal-title":"J Clin Oncol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202000081","article-title":"Aromatase inhibitors: role in postmenopausal breast cancer","volume":"353","author":"Kharb R","year":"2020","unstructured":"Kharb R, Haider K, Neha K, Yar MS. Aromatase inhibitors: role in postmenopausal breast cancer. Arch Pharm (Weinheim). 2020, 353:e2000081. 10.1002\/ardp.202000081","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman RE","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI, et al.. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007, 8:119-27. 10.1016\/S1470-2045(07)70003-7","journal-title":"Lancet Oncol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S29432","article-title":"Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer","volume":"4","author":"Bauer M","year":"2012","unstructured":"Bauer M, Bryce J, Hadji P. Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast Cancer (Dove Med Press). 2012, 4:91-101. 10.2147\/BCTT.S29432","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67036-5","article-title":"Adjuvant aromatase inhibitors for breast cancer","volume":"6","author":"Howell A","year":"2005","unstructured":"Howell A. Adjuvant aromatase inhibitors for breast cancer. Lancet. 2005, 6:431-3. 10.1016\/S0140-6736(05)67036-5","journal-title":"Lancet"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1726-z","article-title":"Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer","volume":"140","author":"Kyvernitakis I","year":"2014","unstructured":"Kyvernitakis I, Rachner TD, Urbschat A, Hars O, Hofbauer LC, Hadji P. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. J Cancer Res Clin Oncol. 2014, 140:1671-80. 10.1007\/s00432-014-1726-z","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3899-6","article-title":"Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer","volume":"28","author":"Hong AR","year":"2017","unstructured":"Hong AR, Kim JH, Lee KH, et al.. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int. 2017, 28:1413-22. 10.1007\/s00198-016-3899-6","journal-title":"Osteoporos Int"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.4172\/2469-6684.100023","article-title":"Adjuvant aromatase inhibitors in early breast cancer may not increase the risk of falls","volume":"2","author":"Choksi P","year":"2016","unstructured":"Choksi P, Williams ME, Kidwel KM, Stella J, Soyster M, Hanauer D, Van Poznak C. Adjuvant aromatase inhibitors in early breast cancer may not increase the risk of falls. J Bone Rep Recomm. 2016, 2:10.4172\/2469-6684.100023","journal-title":"J Bone Rep Recomm"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-19-0077","article-title":"The effects of adjuvant endocrine therapy on bone health in women with breast cancer","volume":"241","author":"Ramchand SK","year":"2019","unstructured":"Ramchand SK, Cheung YM, Yeo B, Grossmann M. The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol. 2019, 241:R111-24. 10.1530\/JOE-19-0077","journal-title":"J Endocrinol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1159\/000505376","article-title":"Fractures due to aromatase inhibitor therapy for breast cancer: a real-world analysis of FAERS data in the past 15 years","volume":"43","author":"Song Y","year":"2020","unstructured":"Song Y, Xu YL, Lin Y, Zhao B, Sun Q. Fractures due to aromatase inhibitor therapy for breast cancer: a real-world analysis of FAERS data in the past 15 years. Oncol Res Treat. 2020, 43:96-102. 10.1159\/000505376","journal-title":"Oncol Res Treat"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e403","article-title":"Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients: a meta-analysis","volume":"35","author":"Lee YK","year":"2020","unstructured":"Lee YK, Lee EG, Kim HY, et al.. Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients: a meta-analysis. J Korean Med Sci. 2020, 35:e403. 10.3346\/jkms.2020.35.e403","journal-title":"J Korean Med Sci"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.09.010","article-title":"Bone health evaluation one year after aromatase inhibitors completion","volume":"117","author":"Pineda-Moncus\u00ed M","year":"2018","unstructured":"Pineda-Moncus\u00ed M, Servitja S, Casamayor G, et al.. Bone health evaluation one year after aromatase inhibitors completion. Bone. 2018, 117:54-9. 10.1016\/j.bone.2018.09.010","journal-title":"Bone"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194831","article-title":"Effectiveness of organized mammography screening for different breast cancer molecular subtypes","volume":"14","author":"Ding L","year":"2022","unstructured":"Ding L, Greuter MJ, Truyen I, et al.. Effectiveness of organized mammography screening for different breast cancer molecular subtypes. Cancers (Basel). 2022, 14:268-75. 10.3390\/cancers14194831","journal-title":"Cancers (Basel)"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2014.12.008","article-title":"Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer","volume":"24","author":"Koopal C","year":"2015","unstructured":"Koopal C, Janssen-Heijnen ML, van de Wouw AJ, van den Bergh JP. Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer. Breast. 2015, 24:153-8. 10.1016\/j.breast.2014.12.008","journal-title":"Breast"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.11080","article-title":"Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy","volume":"2","author":"Pedersini R","year":"2019","unstructured":"Pedersini R, Amoroso V, Maffezzoni F, et al.. Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open. 2019, 2:e1911080. 10.1001\/jamanetworkopen.2019.11080","journal-title":"JAMA Netw Open"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10440","article-title":"The interaction of lean body mass with fat body mass is associated with vertebral fracture prevalence in women with early breast cancer undergoing aromatase inhibitor therapy","volume":"5","author":"Monteverdi S","year":"2021","unstructured":"Monteverdi S, Pedersini R, Gallo F, et al.. The interaction of lean body mass with fat body mass is associated with vertebral fracture prevalence in women with early breast cancer undergoing aromatase inhibitor therapy. JBMR Plus. 2021, 5:e10440. 10.1002\/jbm4.10440","journal-title":"JBMR Plus"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmv059","article-title":"GnRH and GnRH receptors in the pathophysiology of the human female reproductive system","volume":"22","author":"Maggi R","year":"2016","unstructured":"Maggi R, Cariboni AM, Marelli MM, Moretti RM, Andr\u00e8 V, Marzagalli M, Limonta P. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Hum Reprod Update. 2016, 22:358-81. 10.1093\/humupd\/dmv059","journal-title":"Hum Reprod Update"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/s1472-6483(11)60210-1","article-title":"Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action","volume":"5","author":"Ortmann O","year":"2002","unstructured":"Ortmann O, Weiss JM, Diedrich K, et al.. Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online. 2002, 5:1-7. 10.1016\/s1472-6483(11)60210-1","journal-title":"Reprod Biomed Online"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30047-0","article-title":"Bone health during endocrine therapy for cancer","volume":"6","author":"Rachner TD","year":"2018","unstructured":"Rachner TD, Coleman R, Hadji P, et al.. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018, 6:901-10. 10.1016\/S2213-8587(18)30047-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant MF","year":"2007","unstructured":"Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al.. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007, 25:820-8. 10.1200\/JCO.2005.02.7102","journal-title":"J Clin Oncol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman I","year":"2003","unstructured":"Fogelman I, Blake GM, Blamey R, et al.. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int. 2003, 14:1001-6. 10.1007\/s00198-003-1508-y","journal-title":"Osteoporos Int"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.06.005","article-title":"Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy","volume":"127","author":"Dalla Via J","year":"2019","unstructured":"Dalla Via J, Daly RM, Owen PJ, Mundell NL, Rantalainen T, Fraser SF. Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy. Bone. 2019, 127:367-75. 10.1016\/j.bone.2019.06.005","journal-title":"Bone"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11254","article-title":"Effect of androgen-deprivation therapy on bone mineral density in Japanese patients with prostate cancer","volume":"32","author":"Miyazawa Y","year":"2018","unstructured":"Miyazawa Y, Sekine Y, Syuto T, et al.. Effect of androgen-deprivation therapy on bone mineral density in Japanese patients with prostate cancer. In Vivo. 2018, 32:409-12. 10.21873\/invivo.11254","journal-title":"In Vivo"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan SL","year":"2005","unstructured":"Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005, 90:6410-17. 10.1210\/jc.2005-0183","journal-title":"J Clin Endocrinol Metab"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-009-0114-1","article-title":"The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis","volume":"4","author":"Haseen F","year":"2010","unstructured":"Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM. The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv. 2010, 4:128-39. 10.1007\/s11764-009-0114-1","journal-title":"J Cancer Surviv"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07180-8","article-title":"The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy","volume":"35","author":"Van Oostwaard MM","year":"2024","unstructured":"Van Oostwaard MM, Wyers CE, Driessen JHM, et al.. The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy. Osteoporos. 2024, 35:2037-45. 10.1007\/s00198-024-07180-8","journal-title":"Osteoporos"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01125","article-title":"Bone fracture incidence after androgen deprivation therapy-investigational agents: results from Cancer Therapy Evaluation Program-sponsored early phase clinical trials 2006-2013","volume":"10","author":"Myint ZW","year":"2020","unstructured":"Myint ZW, Kunos CA. Bone fracture incidence after androgen deprivation therapy-investigational agents: results from Cancer Therapy Evaluation Program-sponsored early phase clinical trials 2006-2013. Front Oncol. 2020, 10:1125. 10.3389\/fonc.2020.01125","journal-title":"Front Oncol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2022.100459","article-title":"Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: an exploratory analysis","volume":"37","author":"Pantano F","year":"2022","unstructured":"Pantano F, Tramontana F, Iuliani M, et al.. Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: an exploratory analysis. J Bone Oncol. 2022, 37:100459. 10.1016\/j.jbo.2022.100459","journal-title":"J Bone Oncol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010532","article-title":"Osteoporosis and fracture after gastrectomy for stomach cancer: a nationwide claims study","volume":"97","author":"Seo GH","year":"2018","unstructured":"Seo GH, Kang HY, Choe EK. Osteoporosis and fracture after gastrectomy for stomach cancer: a nationwide claims study. Medicine (Baltimore). 2018, 97:e0532. 10.1097\/MD.0000000000010532","journal-title":"Medicine (Baltimore)"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000436","article-title":"Increased risk of osteoporotic fracture in postgastrectomy gastric cancer survivors compared with matched controls: a nationwide cohort study in Korea","volume":"114","author":"Shin DW","year":"2019","unstructured":"Shin DW, Suh B, Lim H, et al.. Increased risk of osteoporotic fracture in postgastrectomy gastric cancer survivors compared with matched controls: a nationwide cohort study in Korea. Am J Gastroenterol. 2019, 114:1735-43. 10.14309\/ajg.0000000000000436","journal-title":"Am J Gastroenterol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000692","article-title":"Bone loss after oophorectomy among high-risk women: an NRG oncology\/gynecologic oncology group study","volume":"23","author":"Hibler EA","year":"2016","unstructured":"Hibler EA, Kauderer J, Greene MH, Rodriguez GC, Alberts DS. Bone loss after oophorectomy among high-risk women: an NRG oncology\/gynecologic oncology group study. Menopause. 2016, 23:1228-32. 10.1097\/GME.0000000000000692","journal-title":"Menopause"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/s0378-5122(03)00040-9","article-title":"Bone density patterns after normal and premature menopause","volume":"25","author":"Hadjidakis DJ","year":"2003","unstructured":"Hadjidakis DJ, Kokkinakis EP, Sfakianakis ME, et al.. Bone density patterns after normal and premature menopause. Maturitas. 2003, 25:279-86. 10.1016\/s0378-5122(03)00040-9","journal-title":"Maturitas"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e318239caeb","article-title":"Surgical menopause and nonvertebral fracture risk among older US women","volume":"19","author":"Vesco KK","year":"2012","unstructured":"Vesco KK, Marshall LM, Nelson HD, et al.. Surgical menopause and nonvertebral fracture risk among older US women. Menopause. 2012, 19:510-16. 10.1097\/gme.0b013e318239caeb","journal-title":"Menopause"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(96)00211-9","article-title":"Fracture risk following bilateral oophorectomy","volume":"49","author":"Melton LJ","year":"1996","unstructured":"Melton LJ, Crowson CS, Malkasian GD, et al.. Fracture risk following bilateral oophorectomy. J Clin Epidemiol. 1996, 49:1111-15. 10.1016\/0895-4356(96)00211-9","journal-title":"J Clin Epidemiol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169673","article-title":"Elevated bone turnover markers after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer","volume":"12","author":"Fakkert IE","year":"2017","unstructured":"Fakkert IE, van der Veer E, Abma EM, et al.. Elevated bone turnover markers after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. PLoS One. 2017, 12:e0169673. 10.1371\/journal.pone.0169673","journal-title":"PLoS One"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3295-7","article-title":"FRAX predicts incident falls in elderly men: findings from MrOs Sweden","volume":"27","author":"Harvey NC","year":"2016","unstructured":"Harvey NC, Johansson H, Od\u00e9n A, et al.. FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporos Int. 2016, 27:267-74. 10.1007\/s00198-015-3295-7","journal-title":"Osteoporos Int"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3331","article-title":"Falls predict fractures independently of FRAX probability: a meta\u2010analysis of the osteoporotic fractures in men (MrOS) study","volume":"33","author":"Harvey NC","year":"2018","unstructured":"Harvey NC, Od\u00e9n A, Orwoll E, et al.. Falls predict fractures independently of FRAX probability: a meta\u2010analysis of the osteoporotic fractures in men (MrOS) study. J Bone Miner Res. 2018, 33:510-16. 10.1002\/jbmr.3331","journal-title":"J Bone Miner Res"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1591","article-title":"High serum adiponectin predicts incident fractures in elderly men: osteoporotic fractures in men (MrOS) Sweden","volume":"27","author":"Johansson H","year":"2012","unstructured":"Johansson H, Od\u00e9n A, Lerner UH, et al.. High serum adiponectin predicts incident fractures in elderly men: osteoporotic fractures in men (MrOS) Sweden. J Bone Miner Res. 2012, 27:1390-6. 10.1002\/jbmr.1591","journal-title":"J Bone Miner Res"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3556","article-title":"Measures of physical performance and muscle strength as predictors of fracture risk independent of FRAX, falls, and aBMD: a meta-analysis of the Osteoporotic Fractures in Men (MrOS) study","volume":"33","author":"Harvey NC","year":"2018","unstructured":"Harvey NC, Od\u00e9n A, Orwoll E, et al.. Measures of physical performance and muscle strength as predictors of fracture risk independent of FRAX, falls, and aBMD: a meta-analysis of the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res. 2018, 33:2150-7. 10.1002\/jbmr.3556","journal-title":"J Bone Miner Res"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-020-03378-z","article-title":"Evaluation of baseline fracture risk in younger postmenopausal women with breast cancer using different risk assessment methods","volume":"49","author":"Schaffler-Schaden D","year":"2020","unstructured":"Schaffler-Schaden D, Kneidinger C, Schweighofer-Zwink G, Flamm M, Iglseder B, Pirich C. Evaluation of baseline fracture risk in younger postmenopausal women with breast cancer using different risk assessment methods. Skeletal Radiol. 2020, 49:1015-19. 10.1007\/s00256-020-03378-z","journal-title":"Skeletal Radiol"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman R","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ, et al.. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020, 31:1650-63. 10.1016\/j.annonc.2020.07.019","journal-title":"Ann Oncol"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605548","article-title":"Assessment of fracture risk in women with breast cancer using current vs emerging guidelines","volume":"102","author":"Hadji P","year":"2010","unstructured":"Hadji P, Ziller M, Albert US, Kalder M. Assessment of fracture risk in women with breast cancer using current vs emerging guidelines. Br J Cancer. 2010, 102:645-50. 10.1038\/sj.bjc.6605548","journal-title":"Br J Cancer"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris ES","year":"2004","unstructured":"Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004, 164:1108-12. 10.1001\/archinte.164.10.1108","journal-title":"Arch Intern Med"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality - the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman E","year":"2006","unstructured":"Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med. 2006, 354:2250-61. 10.1056\/NEJMra053077","journal-title":"N Engl J Med"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1177\/03008916241236279","article-title":"Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey","volume":"110","author":"Valsecchi AA","year":"2024","unstructured":"Valsecchi AA, Fusco V, Di Maio M, et al.. Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey. Tumori. 2024, 110:174-85. 10.1177\/03008916241236279","journal-title":"Tumori"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr017","article-title":"Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment","volume":"22","author":"Hadji P","year":"2011","unstructured":"Hadji P, Aapro MS, Body JJ, et al.. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol. 2011, 22:2546-55. 10.1093\/annonc\/mdr017","journal-title":"Ann Oncol"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809059252","article-title":"Biologic and therapeutic determinants of bone mineral density in multiple myeloma","volume":"32","author":"Dhodapkar MV","year":"1998","unstructured":"Dhodapkar MV, Weinstein R, Tricot G, Jagannath S, Parfitt AM, Manolagas SC, Barlogie B. Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma. 1998, 32:121-7. 10.3109\/10428199809059252","journal-title":"Leuk Lymphoma"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2303","article-title":"Bone mineral density utilization in patients with newly diagnosed multiple myeloma","volume":"35","author":"Muchtar E","year":"2017","unstructured":"Muchtar E, Dagan A, Robenshtok E, et al.. Bone mineral density utilization in patients with newly diagnosed multiple myeloma. Hematol Oncol. 2017, 35:703-10. 10.1002\/hon.2303","journal-title":"Hematol Oncol"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1177\/2151458513501176","article-title":"The value of laboratory tests in diagnosing secondary osteoporosis at a fracture and osteoporosis outpatient clinic","volume":"4","author":"de Klerk G","year":"2013","unstructured":"de Klerk G, Hegeman JH, van der Velde D, van der Palen J, van Bergeijk L, Duis HJ. The value of laboratory tests in diagnosing secondary osteoporosis at a fracture and osteoporosis outpatient clinic. Geriatr Orthop Surg Rehabil. 2013, 4:53-7. 10.1177\/2151458513501176","journal-title":"Geriatr Orthop Surg Rehabil"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2021.03.012","article-title":"Impact of serum calcium levels on total body bone mineral density: a mendelian randomization study in five age strata","volume":"40","author":"Sun JY","year":"2021","unstructured":"Sun JY, Zhang H, Zhang Y, Wang L, Sun BL, Gao F, Liu G. Impact of serum calcium levels on total body bone mineral density: a mendelian randomization study in five age strata. Clin Nutr. 2021, 40:2726-33. 10.1016\/j.clnu.2021.03.012","journal-title":"Clin Nutr"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.2019.26.2.89","article-title":"Preventive effects of low parathyroid hormone levels on hip fracture in patients with vitamin D deficiency","volume":"26","author":"Byun SE","year":"2019","unstructured":"Byun SE, Lee S, Kim JW, et al.. Preventive effects of low parathyroid hormone levels on hip fracture in patients with vitamin D deficiency. J Bone Metab. 2019, 26:89-95. 10.11005\/jbm.2019.26.2.89","journal-title":"J Bone Metab"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2016.09.006","article-title":"Advances in imaging approaches to fracture risk evaluation","volume":"181","author":"Manhard MK","year":"2017","unstructured":"Manhard MK, Nyman JS, Does MD. Advances in imaging approaches to fracture risk evaluation. Transl Res. 2017, 181:1-14. 10.1016\/j.trsl.2016.09.006","journal-title":"Transl Res"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.10.007","article-title":"Axial cortical involvement of metastatic lesions to identify impending femoral fractures; a clinical validation study","volume":"144","author":"van der Wal CW","year":"2020","unstructured":"van der Wal CW, Eggermont F, Fiocco M, et al.. Axial cortical involvement of metastatic lesions to identify impending femoral fractures; a clinical validation study. Radiother Oncol. 2020, 144:59-64. 10.1016\/j.radonc.2019.10.007","journal-title":"Radiother Oncol"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10749","article-title":"Prevalence of precursory signs of atypical femoral fractures in patients receiving bone-modifying agents for bone metastases: a cross-sectional study","volume":"7","author":"Kaku T","year":"2023","unstructured":"Kaku T, Oh Y, Sato S, et al.. Prevalence of precursory signs of atypical femoral fractures in patients receiving bone-modifying agents for bone metastases: a cross-sectional study. JBMR Plus. 2023, 7:e10749. 10.1002\/jbm4.10749","journal-title":"JBMR Plus"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2016.04.011","article-title":"Combining computed tomography-based bone density assessment with FRAX screening in men with prostate cancer","volume":"19","author":"McDonald AM","year":"2016","unstructured":"McDonald AM, Jones JA, Cardan RA, Saag KS, Mayhew DL, Fiveash JB. Combining computed tomography-based bone density assessment with FRAX screening in men with prostate cancer. J Clin Densitom. 2016, 19:430-5. 10.1016\/j.jocd.2016.04.011","journal-title":"J Clin Densitom"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-022-01338-2","article-title":"Risk assessment of femoral pathological fracture in prostate cancer patients by computed tomography analysis","volume":"40","author":"Rikitake H","year":"2022","unstructured":"Rikitake H, Horiuchi K, Miyai K, et al.. Risk assessment of femoral pathological fracture in prostate cancer patients by computed tomography analysis. J Bone Miner Metab. 2022, 40:704-11. 10.1007\/s00774-022-01338-2","journal-title":"J Bone Miner Metab"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.18383\/j.tom.2015.00154","article-title":"Potential for early fracture risk assessment in patients with metastatic bone disease using parametric response mapping of CT images","volume":"1","author":"Hoff BA","year":"2015","unstructured":"Hoff BA, Toole M, Yablon C, Ross BD, Luker GD, VanPoznak C, Galb\u00e1n CJ. Potential for early fracture risk assessment in patients with metastatic bone disease using parametric response mapping of CT images. Tomography. 2015, 1:98-104. 10.18383\/j.tom.2015.00154","journal-title":"Tomography"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-020-10053-z","article-title":"Prediction of pathological fracture in patients with lower limb bone metastasis using computed tomography imaging","volume":"37","author":"Shinoda Y","year":"2020","unstructured":"Shinoda Y, Sawada R, Ishibashi Y, et al.. Prediction of pathological fracture in patients with lower limb bone metastasis using computed tomography imaging. Clin Exp Metastasis. 2020, 37:607-16. 10.1007\/s10585-020-10053-z","journal-title":"Clin Exp Metastasis"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.10.016","article-title":"Validation of biomechanical computed tomography for fracture risk classification in metastatic hormone-sensitive prostate cancer","volume":"7","author":"Lin JK","year":"2024","unstructured":"Lin JK, Hearn CM, Getzen E, et al.. Validation of biomechanical computed tomography for fracture risk classification in metastatic hormone-sensitive prostate cancer. Eur Urol Oncol. 2024, 7:794-803. 10.1016\/j.euo.2023.10.016","journal-title":"Eur Urol Oncol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-015-4371-1","article-title":"Does CT-based rigidity analysis influence clinical decision-making in simulations of metastatic bone disease?","volume":"474","author":"Nazarian A","year":"2016","unstructured":"Nazarian A, Entezari V, Villa-Camacho JC, et al.. Does CT-based rigidity analysis influence clinical decision-making in simulations of metastatic bone disease?. Clin Orthop Relat Res. 2016, 474:652-9. 10.1007\/s11999-015-4371-1","journal-title":"Clin Orthop Relat Res"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2668","article-title":"Treatment planning and fracture prediction in patients with skeletal metastasis with CT-based rigidity analysis","volume":"21","author":"Nazarian A","year":"2015","unstructured":"Nazarian A, Entezari V, Zurakowski D, et al.. Treatment planning and fracture prediction in patients with skeletal metastasis with CT-based rigidity analysis. Clin Cancer Res. 2015, 21:2514-19. 10.1158\/1078-0432.CCR-14-2668","journal-title":"Clin Cancer Res"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.25647","article-title":"MRI assessment of bone structure and microarchitecture","volume":"46","author":"Chang G","year":"2017","unstructured":"Chang G, Boone S, Martel D, et al.. MRI assessment of bone structure and microarchitecture. J Magn Reson Imaging. 2017, 46:323-37. 10.1002\/jmri.25647","journal-title":"J Magn Reson Imaging"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001580","article-title":"FDG PET\/CT assesses the risk of femoral pathological fractures in patients with metastatic breast cancer","volume":"42","author":"Ulaner GA","year":"2017","unstructured":"Ulaner GA, Zindman AM, Zheng J, Kim TW, Healey JH. FDG PET\/CT assesses the risk of femoral pathological fractures in patients with metastatic breast cancer. Clin Nucl Med. 2017, 42:264-70. 10.1097\/RLU.0000000000001580","journal-title":"Clin Nucl Med"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100884","article-title":"Radiomic modeling of bone density and rib fracture risk after stereotactic body radiation therapy for early-stage non-small cell lung cancer","volume":"7","author":"Rydzewski NR","year":"2022","unstructured":"Rydzewski NR, Yadav P, Musunuru HB, Condit KM, Francis D, Zhao SG, Baschnagel AM. Radiomic modeling of bone density and rib fracture risk after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Adv Radiat Oncol. 2022, 7:100884. 10.1016\/j.adro.2021.100884","journal-title":"Adv Radiat Oncol"},{"key":"ref134","article-title":"A patient-specific fracture risk assessment tool for femoral bone metastases: using the bone strength (BOS) score in clinical practice","volume":"29","author":"Eggermont F","year":"2022","unstructured":"Eggermont F, van der Linden Y, Verdonschot N, et al.. A patient-specific fracture risk assessment tool for femoral bone metastases: using the bone strength (BOS) score in clinical practice. Cancers (Basel). 2022, 29:14.","journal-title":"Cancers (Basel)"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2014.08.004","article-title":"Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment","volume":"5","author":"Graham-Steed TR","year":"2014","unstructured":"Graham-Steed TR, Soulos PR, Dearing N, Concato J, Tinetti ME, Gross CP. Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment. J Geriatr Oncol. 2014, 5:343-51. 10.1016\/j.jgo.2014.08.004","journal-title":"J Geriatr Oncol"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2018.02.001","article-title":"Assessing the utility of the spinal instability neoplastic score (SINS) to predict fracture after conventional radiation therapy (RT) for spinal metastases","volume":"8","author":"Shi DD","year":"2018","unstructured":"Shi DD, Hertan LM, Lam TC, et al.. Assessing the utility of the spinal instability neoplastic score (SINS) to predict fracture after conventional radiation therapy (RT) for spinal metastases. Pract Radiat Oncol. 2018, 8:e285-94. 10.1016\/j.prro.2018.02.001","journal-title":"Pract Radiat Oncol"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.OA.22.00070","article-title":"Predicting pathological fractures at metastatic humeral lesions","volume":"8","author":"Tat J","year":"2023","unstructured":"Tat J, Bodansky D, Sheth U, Ung Y, Whyne C, Nam D. Predicting pathological fractures at metastatic humeral lesions. JB JS Open Access. 2023, 8:10.2106\/JBJS.OA.22.00070","journal-title":"JB JS Open Access"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1188\/05.onf.589-603","article-title":"Cancer treatment-induced bone loss in patients with breast or prostate cancer","volume":"32","author":"Maxwell C","year":"2005","unstructured":"Maxwell C, Viale PH. Cancer treatment-induced bone loss in patients with breast or prostate cancer. Oncol Nurs Forum. 2005, 32:589-603. 10.1188\/05.onf.589-603","journal-title":"Oncol Nurs Forum"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1038\/bonekey.2014.69","article-title":"A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures","volume":"3","author":"Abrahamsen B","year":"2014","unstructured":"Abrahamsen B, Brask-Lindemann D, Rubin KH, Schwarz P. A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures. Bonekey Rep. 2014, 3:574. 10.1038\/bonekey.2014.69","journal-title":"Bonekey Rep"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020201","article-title":"Spinal stabilization exercises for cancer patients with spinal metastases of high fracture risk: feasibility of the DISPO-II training program","volume":"13","author":"Rosenberger F","year":"2021","unstructured":"Rosenberger F, Sprave T, Clauss D, et al.. Spinal stabilization exercises for cancer patients with spinal metastases of high fracture risk: feasibility of the DISPO-II training program. Cancers (Basel). 2021, 13:13. 10.3390\/cancers13020201","journal-title":"Cancers (Basel)"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0000000000001831","article-title":"Exercise mode specificity for preserving spine and hip bone mineral density in prostate cancer patients","volume":"51","author":"Newton RU","year":"2019","unstructured":"Newton RU, Galv\u00e3o DA, Spry N, et al.. Exercise mode specificity for preserving spine and hip bone mineral density in prostate cancer patients. Med Sci Sports Exerc. 2019, 51:607-14. 10.1249\/MSS.0000000000001831","journal-title":"Med Sci Sports Exerc"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2007.10.005","article-title":"Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer","volume":"34","author":"Hadji P","year":"2007","unstructured":"Hadji P, Bundred N. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Semin Oncol. 2007, 34:S4-10. 10.1053\/j.seminoncol.2007.10.005","journal-title":"Semin Oncol"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline","volume":"37","author":"Shapiro CL","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C, et al.. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019, 37:2916-46. 10.1200\/JCO.19.01696","journal-title":"J Clin Oncol"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2016.03.010","article-title":"Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: a randomized, controlled clinical trial","volume":"90","author":"Prasad C","year":"2016","unstructured":"Prasad C, Greenspan SL, Vujevich KT, et al.. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: a randomized, controlled clinical trial. Bone. 2016, 90:123-6. 10.1016\/j.bone.2016.03.010","journal-title":"Bone"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000696","article-title":"Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women\u2019s Health Initiative","volume":"23","author":"Drieling RL","year":"2016","unstructured":"Drieling RL, LaCroix AZ, Beresford SA, et al.. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women\u2019s Health Initiative. Menopause. 2016, 23:1168-75. 10.1097\/GME.0000000000000696","journal-title":"Menopause"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0000000000000647","article-title":"Selective estrogen receptor modulators in gynecology practice","volume":"64","author":"Pinkerton JV","year":"2021","unstructured":"Pinkerton JV. Selective estrogen receptor modulators in gynecology practice. Clin Obstet Gynecol. 2021, 64:803-12. 10.1097\/GRF.0000000000000647","journal-title":"Clin Obstet Gynecol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357795-understanding-and-managing-fracture-risk-in-patients-with-cancer-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T16:21:50Z","timestamp":1745770910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357795-understanding-and-managing-fracture-risk-in-patients-with-cancer-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,27]]},"references-count":146,"URL":"https:\/\/doi.org\/10.7759\/cureus.83082","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,27]]}}}